🇺🇸 erenumab-aooe in United States

2,031 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 2,031

Most-reported reactions

1. Off Label Use — 304 reports (14.97%)
2. Drug Ineffective — 261 reports (12.85%)
3. Migraine — 220 reports (10.83%)
4. Drug Intolerance — 210 reports (10.34%)
5. Pain — 185 reports (9.11%)
6. Gastrooesophageal Reflux Disease — 179 reports (8.81%)
7. Headache — 174 reports (8.57%)
8. Product Use In Unapproved Indication — 168 reports (8.27%)
9. Abdominal Pain Upper — 167 reports (8.22%)
10. Blepharospasm — 163 reports (8.03%)

Source database →

Frequently asked questions

Is erenumab-aooe approved in United States?

erenumab-aooe does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for erenumab-aooe in United States?

Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.